Dr. John Goldman CML Chronic Myeloid Leukemia
''Professor John M. Goldman has a long standing interest in the biology and therapy of chronic myeloid leukemia (CML)....
....He is now active as Emeritus Professor of Haematology at Imperial College London and Medical Director of the Anthony Nolan Trust....
... Professor Goldman was the first to autograft patients with CML using peripheral blood stem cells and started allogeneic stem cell transplant for CML in 1980. He pioneered the use of unrelated donors for transplanting CML patients and developed PCR technology for monitoring residual disease. He confirmed the preclinical efficacy of the original tyrosine kinase inhibitor (STI571, now imatinib) in 1997 and first used it in the clinic in 1999. Thereafter he has been involved in development of second generation TKIs, notably dasatinib and nilotinib.""
Extract from the site of iCMLf (International Chronic Myeloid Leukemia Foundation)
VIDEOS
CML Treatment with imatinib
December 2010, iCMLf
Novel agents for treatment of CML with Prof. John Goldman – EHA 2010
August 5, 2010, ecancer.tv
CML Treatment with imatinib
December 2010, iCMLf
Novel agents for treatment of CML with Prof. John Goldman – EHA 2010
August 5, 2010, ecancer.tv
